| BPC-157 (Body Protection Compound 157) is a synthetic peptide derived from a protein fragment found in human gastric juice, studied for potential roles in tissue repair, inflammation regulation, and gastrointestinal protection
Glucagon receptor activation increases energy expenditure directly by stimulating thermogenesis in adipose tissue and hepatic fat oxidation
Some people with the condition don't have any symptoms, at least at first
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Higher-Caution Situations Extra medical supervision is important if you: have a history of reactions to injectable vitamins/cobalamins have significant kidney or liver disease are pregnant or breastfeeding are offered a compounded MIC B12 product without clear labeling of ingredients, concentrations, and compounding source The FDAs overview of compounding helps explain why quality can vary (see Compounding and the FDA: Questions and Answers )
Lets not add BPC-157 to that list by rushing ahead of the evidence